These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 37881221

  • 21. Hepatic arterial infusion chemotherapy versus transarterial chemoembolization for unresectable hepatocellular carcinoma: A systematic review with meta-analysis.
    Si T, Huang Z, Khorsandi SE, Ma Y, Heaton N.
    Front Bioeng Biotechnol; 2022; 10():1010824. PubMed ID: 36237208
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. Efficacy and Safety of Hepatic Arterial Infusion Chemotherapy(HAIC) Combined with PD-1 Inhibitors for Advanced Hepatocellular Carcinoma with Macrovascular Invasion: A Multicenter Propensity Score Matching Analysis.
    Zhang F, Zhong S, Wei Q, Zhang H, Hu H, Zeng B, Zheng X.
    J Hepatocell Carcinoma; 2024; 11():1961-1978. PubMed ID: 39429914
    [Abstract] [Full Text] [Related]

  • 24. Transarterial Chemoembolization Combined with Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors versus Immune Checkpoint Inhibitors Plus Tyrosine Kinase Inhibitors for Advanced Hepatocellular Carcinoma.
    Huang JT, Zhong BY, Jiang N, Li WC, Zhang S, Yin Y, Yang J, Shen J, Wang WS, Zhu XL.
    J Hepatocell Carcinoma; 2022; 9():1217-1228. PubMed ID: 36474670
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The safety and efficacy of TACE combined with HAIC, PD-1 inhibitors, and tyrosine kinase inhibitors for unresectable hepatocellular carcinoma: a retrospective study.
    Huang Z, Wu Z, Zhang L, Yan L, Jiang H, Ai J.
    Front Oncol; 2024; 14():1298122. PubMed ID: 38318115
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Conversion to Resectability Using Transarterial Chemoembolization Combined With Hepatic Arterial Infusion Chemotherapy for Initially Unresectable Hepatocellular Carcinoma.
    Li B, Qiu J, Zheng Y, Shi Y, Zou R, He W, Yuan Y, Zhang Y, Wang C, Qiu Z, Li K, Zhong C, Yuan Y.
    Ann Surg Open; 2021 Jun; 2(2):e057. PubMed ID: 37636551
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors.
    Guan R, Zhang N, Deng M, Lin Y, Huang G, Fu Y, Zheng Z, Wei W, Zhong C, Zhao H, Mei J, Guo R.
    Int J Surg; 2024 Jul 01; 110(7):4062-4073. PubMed ID: 38549220
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. Hepatic Arterial Infusion Chemotherapy Using Oxaliplatin Plus 5-Fluorouracil Versus Transarterial Chemoembolization/Embolization for the Treatment of Advanced Hepatocellular Carcinoma with Major Portal Vein Tumor Thrombosis.
    Hu J, Bao Q, Cao G, Zhu X, Yang R, Ji X, Xu L, Zheng K, Li W, Xing B, Wang X.
    Cardiovasc Intervent Radiol; 2020 Jul 01; 43(7):996-1005. PubMed ID: 31974744
    [Abstract] [Full Text] [Related]

  • 34. PD-1 Inhibitors Combined with Antiangiogenic Therapy with or Without Transarterial Chemoembolization in the Treatment of Hepatocellular Carcinoma: A Propensity Matching Analysis.
    Li H, Su K, Guo L, Jiang Y, Xu K, Gu T, Chen J, Wu Z, Wang P, Zhang X, Yan Y, Li S, Wu X, Han L, He K, Wen L, Li B, Han Y.
    J Hepatocell Carcinoma; 2023 Jul 01; 10():1257-1266. PubMed ID: 37538403
    [Abstract] [Full Text] [Related]

  • 35. Beneficial effects of maintaining liver function during hepatic arterial infusion chemotherapy combined with tyrosine kinase and programmed cell death protein-1 inhibitors on the outcomes of patients with unresectable hepatocellular carcinoma.
    Xiao Y, Deng W, Luo L, Zhu G, Xie J, Liu Y, Wan R, Wen W, Hu Z, Shan R.
    BMC Cancer; 2024 May 14; 24(1):588. PubMed ID: 38745113
    [Abstract] [Full Text] [Related]

  • 36. Transarterial chemoembolization plus lenvatinib with or without programmed death-1 inhibitors for patients with unresectable hepatocellular carcinoma: A propensity score matching study.
    Guo P, Pi X, Gao F, Li Q, Li D, Feng W, Cao W.
    Front Oncol; 2022 May 14; 12():945915. PubMed ID: 36338683
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil, and Leucovorin Versus Transarterial Chemoembolization for Large Hepatocellular Carcinoma: A Randomized Phase III Trial.
    Li QJ, He MK, Chen HW, Fang WQ, Zhou YM, Xu L, Wei W, Zhang YJ, Guo Y, Guo RP, Chen MS, Shi M.
    J Clin Oncol; 2022 Jan 10; 40(2):150-160. PubMed ID: 34648352
    [Abstract] [Full Text] [Related]

  • 39. Transarterial Chemoembolization Combined with Tyrosine Kinase Inhibitors Plus Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
    Gao B, Yang F, Zheng D, Hu S, Liu J, Liu H, Liu Y, Liu L, Wang R, Zhao Y, Cui C, Fang C, Yang J, Su S, Han Y, Yang X, Li B.
    J Hepatocell Carcinoma; 2023 Jan 10; 10():2265-2276. PubMed ID: 38107541
    [Abstract] [Full Text] [Related]

  • 40.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.